Recent Company News

• 11:41 AM ET May 01, 2026
  

  FDA approves Arexvy sBLA for prefilled syringe (1904.0000p, 0)

• 10:46 AM ET May 01, 2026
  

  UK MHRA approves Lynavoy (linerixibat) for itch in adults with PBC (1911.0000p, -17)

• 11:05 AM ET Apr 30, 2026
  

  HHS formally files appeal of preliminary injunction in CDC ACIP case

• 09:10 AM ET Apr 30, 2026
  

  Street Takeaways - GSK Plc Q1 earnings (1949.0000p, +31)

• 08:53 AM ET Apr 30, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:04 AM ET Apr 30, 2026
  

  GSK Canada secures priority review for regulatory submission of bepirovirsen (1940.0000p, +22)

• 09:11 PM ET Apr 29, 2026
  

  NICE recommends GSK's Blenrep with bortezomib and dexamethasone for previously treated multiple myeloma (1918.0000p, 0)

• 05:04 PM ET Apr 29, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:14 PM ET Apr 29, 2026
  

  Alector to discontinue phase 2 progress-ad trial of Nivisnebart (AL101/GSK4527226) in early Alzheimer's disease following interim futility analysis ($2.30, 0.00)

• 03:00 PM ET Apr 29, 2026
  

  FDA approves sBLA for AREPANRIX (pediatric) with Accelerated Approval and post-marketing requirement (1918.0000p, 0)